1.Study of the role of spleen in idiopathic portal hypertension.
Li WANG ; Wei HAN ; Tao ZHOU ; Meng-biao YUAN
Chinese Journal of Hepatology 2006;14(2):133-134
2.The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension.
Clinical and Molecular Hepatology 2012;18(4):337-346
Because of the anatomical position and its unique vascular system, the liver is susceptible to the exposure to the microbial products from the gut. Although large amount of microbes colonize in the gut, translocation of the microbes or microbial products into the liver and systemic circulation is prevented by gut epithelial barrier function and cleansing and detoxifying functions of the liver in healthy subjects. However, when the intestinal barrier function is disrupted, large amount of bacterial products can enter into the liver and systemic circulation and induce inflammation through their receptors. Nowadays, there have been various reports suggesting the role of gut flora and bacterial translocation in the pathogenesis of chronic liver disease and portal hypertension. This review summarizes the current knowledge about bacterial translocation and its contribution to the pathogenesis of chronic liver diseases and portal hypertension.
Antigens, CD14/metabolism
;
Bacterial Translocation
;
Gastrointestinal Tract/*microbiology
;
Humans
;
Hypertension, Portal/metabolism/*pathology
;
Liver/metabolism/*microbiology
;
Liver Cirrhosis/metabolism/*pathology
;
Receptors, Cytoplasmic and Nuclear/metabolism
;
Toll-Like Receptors/metabolism
3.Chronic arsenic poisoning and idiopathic portal hypertension: report of a case.
Zheng WANG ; Ying JIANG ; Chong-qing YANG ; Dong-ge LIU
Chinese Journal of Pathology 2012;41(7):487-488
Adult
;
Arsenic Poisoning
;
pathology
;
Chronic Disease
;
Hemosiderin
;
metabolism
;
Hemosiderosis
;
metabolism
;
pathology
;
Humans
;
Hypertension, Portal
;
chemically induced
;
metabolism
;
pathology
;
Liver Cirrhosis
;
chemically induced
;
metabolism
;
pathology
;
Male
;
Pancytopenia
;
chemically induced
;
metabolism
;
pathology
;
Splenomegaly
;
chemically induced
;
metabolism
;
pathology
4.The lymphatic vascular system in liver diseases: its role in ascites formation.
Clinical and Molecular Hepatology 2013;19(2):99-104
The lymphatic system is part of the circulatory system and plays a key role in normal vascular function. Its failure plays a crucial role in the development and maintenance of various diseases including liver diseases. Lymphangiogenesis (the growth of lymphatic vessels) and changes in the properties of lymphatic vessels are associated with pathogenesis of tumor metastases, ascites formation, liver fibrosis/cirrhosis and portal hypertension. Despite its significant role in liver diseases and its importance as a potential therapeutic target for those diseases, the lymphatic vascular system of the liver is poorly understood. Therefore, how the lymphatic vascular system in general and lymphangiogenesis in particular are mechanistically related to the pathogenesis and maintenance of liver diseases are largely unknown. This article summarizes: 1) the lymphatic vascular system; 2) its role in liver tumors, liver fibrosis/cirrhosis and portal hypertension; and 3) its role in ascites formation.
Ascites/*etiology
;
Humans
;
Hypertension, Portal/complications/pathology
;
Liver Cirrhosis/complications/pathology
;
Liver Diseases/complications/*pathology
;
Liver Neoplasms/complications/pathology
;
Lymphangiogenesis
;
Lymphatic Vessels/metabolism/physiopathology
5.Pathological morphology alteration of the splanchnic vascular wall in portal hypertensive patients.
Zhen YANG ; Li ZHANG ; Dapeng LI ; Fazu QIU
Chinese Medical Journal 2002;115(4):559-562
OBJECTIVETo investigate the pathological morphology alteration of the splanchnic vascular wall in portal hypertensive patients.
METHODSSplenic arteries, veins and gastric coronary veins from portal hypertensive patients (n = 50) were removed during esophagogastric devascularization with splenectomy and were observed under optic and electron microscopes. The expression of iNOS in the splenic artery wall was analysed with immunohistochemistry.
RESULTSThe internal elastic membrane and medial elastic fibers of the splenic artery wall were broken and degenerated. Atrophy, apoptosis and phenotypic changes were seen in smooth muscle cells of splenic arteries. Positive staining for iNOS was seen in the cytoplasm of smooth muscle cells and iNOS activity was elevated compared with the non-cirrhotic patients (P < 0.01). In the splenic and gastric coronary veins of cirrhotic patients, we found proliferative intima, extensive thrombi adhering to the venous wall, mimicked arteriosclerosis plaques accompanied with hypertrophy of smooth muscle cells, and thickened muscle fibers of veins with increase in extracellular matrix.
CONCLUSIONPortal hypertension may be complicated by splanchnic arterial and venous vasculopathy. There may be an interactive relationship among portal hypertension, splanchnic hyperdynamic disturbances and splanchnic vasculopathy in the pathogenesis of portal hypertension.
Adult ; Female ; Humans ; Hypertension, Portal ; metabolism ; pathology ; Immunohistochemistry ; Male ; Microscopy, Electron ; Muscle, Smooth, Vascular ; pathology ; ultrastructure ; Nitric Oxide Synthase ; metabolism ; Nitric Oxide Synthase Type II ; Splenic Artery ; metabolism ; pathology ; ultrastructure ; Splenic Vein ; metabolism ; pathology ; ultrastructure ; Veins ; metabolism ; pathology ; ultrastructure
6.cDNA microarray-based screening of differentially expressed genes in macrophages in the spleen of patients with portal hypertension and hypersplenism.
Feng YAN ; Wei LI ; Jun-tian CHEN ; Yong-ming ZENG ; Yu-wen GUO ; Fei-ran ZHANG ; Zong-fang LI
Journal of Southern Medical University 2006;26(11):1548-1551
OBJECTIVETo identify the differentially expressed genes associated with hypersplenism in patients with portal hypertension.
METHODSThe total RNA were extracted from the macrophages isolated from normal spleen and the spleen of patients with portal hypertension and reversely transcribed to cDNA with the incorporation of fluorescent (cy3 and cy5)-labeled dCTP to prepare the hybridization probes. After hybridization of Biostar-H140s chip containing 14,112 spots of cDNAs with the prepared probes, the gene chip was scanned for fluorescence intensity to screen the differently expressed genes. Three gene chips were used for hybridization and only the genes with differential expression in all the three chips were considered to associate with hypersplenism in patients with portal hypertension.
RESULTSTotaling 896, 1330 and 898 genes were identified to be differentially expressed by the three chips, respectively, and 121 genes (0.86%) showed differential expression in all the three chips, including 21 up-regulated known genes and 73 down-regulated known genes. The differently expressed genes were functionally related with ion channels and transport proteins, cyclins, cytoskeleton, cell receptors, cell signal transduction, metabolism, immunity, and so forth. These genes might be involved in hypersplenism in the condition of portal hypertension.
CONCLUSIONcDNA microarray-based screening of differentially expressed genes in the macrophages in the spleen may provide new insights into the pathogenesis of hypersplenism in patients with portal hypertension.
Female ; Gene Expression Profiling ; Humans ; Hypersplenism ; etiology ; genetics ; Hypertension, Portal ; complications ; genetics ; Macrophages ; metabolism ; Male ; Oligonucleotide Array Sequence Analysis ; methods ; Spleen ; metabolism ; pathology
7.Effects of hepatotrophic factors on the liver after portacaval shunt in rats with portal hypertension.
Zhong-tao ZHANG ; Peng JIANG ; Yu WANG ; Jian-She LI ; Jian-guo XUE ; Yan-zhong ZHOU ; Zhu YUAN
Chinese Medical Journal 2006;119(20):1727-1733
BACKGROUNDPortacaval shunt (PCS) prevent hepatotrophic factors from flowing into the liver, but they enter directly the systemic circulation and worsen liver injury. This study was designed to investigate the effects of hepatotrophic factors through the portal vein on the liver in rats with portal hypertension after portacaval shunt.
METHODSIntrahepatic portal hypertension (IHPH) was induced by intragastric administration of carbon tetrachloride, and end-to-side PCS was performed. Eight normal rats served as controls, and eight rats with IHPH served as IHPH model (IHPH group). Another 32 rats with IHPH-PCS were randomly subdivided into 4 groups: normal saline (NS) given to 8 rats, hepatocyte growth factor (HGF) 8, insulin (INS) 8, hepatocyte growth factor and insulin (HGF + INS) 8. Hepatotrophic factors were infused into the portal vein through an intravenous catheter. Portal venous pressure (PVP) was measured. The levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were tested biochemically and those of hyaluronic acid (HA) and laminin (LN) were measured by radioimmunoassay. Hepatic fibrosis was assessed histologically and the expression of collagens type I and III were detected immunohistochemically. Ultrastructural change of hepatocytes and the number of mitochondria were observed under an electron microscope. The data were compared between groups and subgroups by Student-Newman-Keuls procedure with SPSS10.0.
RESULTSPVP was significantly higher in the IHPH rats than in the control rats (P < 0.05). The levels of serum ALT, AST, HA, and LN, hepatic fibrosis score, the amount of collagen deposition, collagens type I and III increased more significantly in the IHPH group than in the control rats (P < 0.05). The number of mitochondria decreased more significantly in the IHPH rats than in the control rats (P < 0.05). The levels of serum ALT, AST, HA and LN as well as hepatic fibrosis score, the amount of collagen deposition, and the amount of collagens type I and III in the HGF and HGF + INS rats were significantly lower than those in the NS rats (P < 0.05). The damage to hepatocyte ultrastructure was markedly alleviated and the number of mitochondria was increased more significantly in the HGF and HGF + INS rats than in the NS rats under an electron microscope.
CONCLUSIONSPerfusion of exogenous hepatotrophic factors through the portal vein can alleviate liver injury, minimize the damage to the ultrastructure of hepatocyte, protect liver function, and lessen hepatic fibrosis in rats with portal hypertension after PCS.
Alanine Transaminase ; blood ; Animals ; Aspartate Aminotransferases ; blood ; Extracellular Matrix ; metabolism ; Hepatocyte Growth Factor ; pharmacology ; Hypertension, Portal ; metabolism ; pathology ; surgery ; Insulin ; pharmacology ; Liver ; drug effects ; pathology ; ultrastructure ; Liver Cirrhosis, Experimental ; drug therapy ; Male ; Portacaval Shunt, Surgical ; Rats ; Rats, Sprague-Dawley
8.The protective effect of N-acetylcysteine magnesium against liver cirrhosis with portal hypertension in rat.
Rang-Xiao ZHUANG ; Fu-Gen WANG ; Hong-Ping ZHOU ; Ting-Ting SHI ; Shou-Rong LIU
Chinese Journal of Experimental and Clinical Virology 2012;26(5):366-369
OBJECTIVETo study the effects of acetylcysteine magnesium on the vasoactive substances and hepatic fibrosis indexes in liver cirrhosis and portal hypertension of rats.
METHODSThe rat liver cirrhosis model was made with 12 microg/kg dimethylnitrosamines. Then acetylcysteine magnesium was injected respectively with 25, 50, and 100 mg x kg(-1) dose daily into abdominal cavity. After 8 weeks treatment, pathological section, TGF-beta1, NO, TNOS and iNOS of hepatic tissue were detected to assess the effect of acetylcysteine magnesium against cirrhosis portal hypertension.
RESULTSAfter the DMNA modeling was completed, the HE and Sweet reticulocyte staining of liver pathological section showed that cirrhosis of the liver was in the III-IV phase, the infiltration of lymphocytes and formation of pseudolobuli in liver were alleviated in three acetylcysteine magnesium treatment groups (low, medium, and high dose), and the degree of liver fiber sclerosis in three groups was significantly lower than control group. Compared with control group, TGF-beta1, NO, TNOS and iNOS were significantly reduced in all treatment groups (P < 0.05).
CONCLUSIONAcetylcysteine magnesium is probably a distinctive antioxidant which can remove various free radical in body and modulate ligand-dependent signal transduction and the growth of cell. It also have protection in the liver cirrhosis and portal hypertension of rats induced by dimethylnitrosamine.
Acetylcysteine ; therapeutic use ; Animals ; Hypertension, Portal ; metabolism ; pathology ; prevention & control ; Liver Cirrhosis, Experimental ; metabolism ; pathology ; prevention & control ; Male ; Nitric Oxide ; physiology ; Rats ; Rats, Sprague-Dawley ; Transforming Growth Factor beta1 ; analysis
9.Relationship between Tetrahydrobiopterin and Portal Hypertension in Patients with Chronic Liver Disease.
Won Ki HONG ; Kwang Yong SHIM ; Soon Koo BAIK ; Moon Young KIM ; Mee Yon CHO ; Yoon Ok JANG ; Young Shik PARK ; Jin HAN ; Gaeun KIM ; Youn Zoo CHO ; Hye Won HWANG ; Jin Hyung LEE ; Myeong Hun CHAE ; Sang Ok KWON
Journal of Korean Medical Science 2014;29(3):392-399
Tetrahydrobiopterin (BH4) is an essential cofactor in NO synthesis by endothelial nitric oxide synthase (eNOS) enzymes. It has been previously suggested that reduced intrahepatic BH4 results in a decrease in intrahepatic NO and contributes to increased hepatic vascular resistance and portal pressure in animal models of cirrhosis. The main aim of the present study was to evaluate the relationship between BH4 and portal hypertension (PHT). One hundred ninety-three consecutive patients with chronic liver disease were included in the study. Liver biopsy, measurement of BH4 and hepatic venous pressure gradient (HVPG) were performed. Hepatic fibrosis was classified using the Laennec fibrosis scoring system. BH4 levels were determined in homogenized liver tissues of patients using a high performance liquid chromatography (HPLC) system. Statistical analysis was performed to evaluate the relationship between BH4 and HVPG, grade of hepatic fibrosis, clinical stage of cirrhosis, Child-Pugh class. A positive relationship between HVPG and hepatic fibrosis grade, clinical stage of cirrhosis and Child-Pugh class was observed. However, the BH4 level showed no significant correlation with HVPG or clinical features of cirrhosis. BH4 concentration in liver tissue has little relation to the severity of portal hypertension in patients with chronic liver disease.
Adult
;
Aged
;
Biopterin/*analogs & derivatives/analysis
;
*Chromatography, High Pressure Liquid
;
Chronic Disease
;
Elasticity Imaging Techniques
;
Female
;
Hepatic Veins/physiology
;
Humans
;
Hypertension, Portal/complications/*diagnosis/metabolism
;
Liver/pathology
;
Liver Cirrhosis/ultrasonography
;
Liver Diseases/complications/*diagnosis/metabolism
;
Male
;
Middle Aged
;
Nitric Oxide/metabolism
;
Portal Pressure
;
Regression Analysis
;
Severity of Illness Index
10.Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia.
The Korean Journal of Gastroenterology 2010;56(3):186-191
Portal hypertensive gastropathy (PHG) is a term used to define the endoscopic findings of gastric mucosa with a characteristic mosaic-like pattern with or without red spots, and a common finding in patients with portal hypertension. These endoscopic findings correspond to dilated mucosal capillaries without inflammation. The pathogenesis of PHG in not well known, but portal hypertension and some humoral factors seem to be crucial factors for its development. Pharmacological (e.g. propranolol), or interventional radiological (such as transjugular intrahepatic portosystemic shunt) procedures may be useful in preventing re-bleeding from PHG. The classic features of gastric antral vascular ectasia (GAVE) syndrome include red, often haemorrhagic lesions predominantly located in the gastric antrum which can result in significant blood loss. Although the pathogenesis of GAVE is not clearly defined, it seems to be a separate disease entity from PHG, because GAVE generally does not respond to a reduction of portal pressures. Endoscopic ablation (such as argon plasma coagulation) is the first-line treatment of choice. This review will focus on the incidence, clinical importance, etiology, pathophysiology, and treatment of PHG and GAVE syndrome in the setting of portal hypertension.
Esophageal and Gastric Varices/*diagnosis/etiology/therapy
;
Gastric Antral Vascular Ectasia/*diagnosis/etiology/therapy
;
Gastric Mucosa/metabolism/pathology
;
Humans
;
Hypertension, Portal/*complications
;
Portasystemic Shunt, Transjugular Intrahepatic
;
Vasodilator Agents/therapeutic use